

Routes to N-glycinamide oxazolidinone derivatives: The reaction of 4-trityloxymethyl-3-oxa-1-azabicyclo[3.1.0]hexan-2-one with active halides

Zilong Zheng and Stephen C. Bergmeier*

Department of Chemistry & Biochemistry, Clippinger Laboratories, Ohio University, Athens, OH, 45701, USA

Email: bergmeis@ohio.edu

To Professor George Kraus for bringing to life my interest in organic chemistry


Received 11-12-2018

Accepted 01-19-2019

Published on line 01-26-2019

Abstract

N-Glycinamide oxazolidinones are key intermediates for the synthesis of a new class of peptidomimetics. We report, herein, the synthesis of a series of 3,4,5-trisubstituted oxazolidinones with a glycine residue at N-3 of the oxazolidinone ring. Substituents at C-4 and C-5 contain substitution capabilities which are amenable for the introduction of additional peptide chains. The synthesis of the key N-Glycinamide oxazolidinone is made possible through two reactions; a tandem aziridine ring opening/oxazolidinone alkylation and, subsequently, a fused-lactone ring opening by an amine which leads to the N-Glycinamide oxazolidinones.



Keywords: Fused-ring aziridines, oxazolidinones, peptidomimetics, lactones, bicyclic

Introduction

Peptides continue to be a source of inspiration for the design of therapeutic molecules. Modification of the peptide backbone to generate peptidomimetics provides a route to use both the sequence information of peptides as well as stability and structural constraints imposed by the synthetic components.¹⁻³ Oxazolidinones and related linkers have been used previously to prepare a variety of peptidomimetics. The use of both the oxazolidin-4-one type rings (**1**)⁴ as well as oxazolidine-2-one rings (**2**)⁵⁻⁹ (Figure 1) have been reported. In both cases, the oxazolidinone ring has generally been used to induce formation of secondary structures. In the reported oxazolidine-2-one peptidomimetics, the oxazolidinone ring is acylated with an amino acid or peptide chain, while the 4-position contains a carboxylate group used to acylate the nitrogen of a second peptide chain.





Figure 1. Examples of oxazolidinone containing peptidomimetics.

We were interested in generating a unique set of oxazolidinone-based peptidomimetics such as **3** in which the nitrogen on the oxazolidinone ring would be alkylated with a peptide chain. A substituted methyl group (X = O, N or halogen) on the 4-position would allow for attachment of an additional peptide chain. The hydroxymethyl group at C-5 would be available to attach additional functionality to aid in solubility or target identification. It was anticipated that **3** could be prepared from an oxazolidinone such as **4** through modification of the C-4 hydroxymethyl group. Oxazolidinone **4** could be available via an aziridine ring opening/alkylation sequence starting with fused ring aziridine **5** (Scheme 1).




Scheme 1. Proposed route for preparing oxazolidinone-based peptidomimetics.

We have previously shown the utility of aziridines such as **5**¹⁰ for the preparation of natural products such as bestatin¹¹, as well as inhibitors of the transcription read-through in an RNA riboswitch.^{10,12-14} We were intrigued with the possibility of an initial reaction of the aziridine of **5** with a reactive alkyl halide that might be followed by aziridine ring opening with a nucleophile to provide **4** or related oxazolidinones. Similar types of

reactions have been reported by Pinhas et al.¹⁵ The addition reaction of an N-acylaziridine (e.g., **5**) and reactive halides has, however, remained relatively unexplored. Consequently, we propose that reaction of aziridine **5** with a reactive halide should result in the N-alkylation of the oxazolidinone and concomitant ring opening.

Results and Discussion

Based on this hypothesis, the addition reaction of the fused-ring aziridine (**5**) and an iodoacetate was examined. Reaction of aziridine **5** with t-butyl iodoacetate (**6a**) in refluxing CH₃CN provided a moderate yield of the desired oxazolidinone **7a** (Scheme 2).



Scheme 2. Reaction of aziridine **5** with an iodoacetate.


Several solvents, additives and temperatures were examined in order to optimize the reaction conditions (Table 1). Using dried CH₃CN, as opposed to the slightly wet CH₃CN from the reagent bottle, provided a moderate increase in yield of the reaction. Use of a more polar solvent such as DMF provided a poorer yield of the product (entry 3), while THF provided **7a** in a similar yield as wet CH₃CN. Neither acetone nor dioxane provided any of the expected oxazolidinone **7a**.

Table 1. Reaction-optimization conditions for the reaction of fused-ring aziridine and iodoacetate

Entry	Solvent/Additive	Conditions	Yield (%)
1	CH ₃ CN	Reflux	51
2	CH ₃ CN ^a	Reflux	61
3	DMF	10 °C	28
4	THF	Reflux	42
5	Acetone	Reflux	0
6	1,4-Dioxane	Reflux	0
7	CH ₃ CN ^a /NaI	Reflux	83


^aDried by distillation.

Mechanistically, the reaction could proceed via an initial iodide-mediated aziridine-ring opening leading to intermediate **A**, which would be followed by an alkylation to provide **7a**, as shown in Scheme 3. Alternatively, the alkylation of the aziridine with **6a** could occur first to provide the intermediate aziridinium **B**.¹⁶⁻¹⁸ This would be followed by ring opening with iodide to provide **7a**. Additional NaI resulted in a significant increase in overall yield of the alkylated oxazolidinone, suggesting that the reaction proceeds via an initial ring opening followed by alkylation.



Scheme 3. Possible mechanistic rationale for the reaction of **5** with an iodoacetate.

With good reaction conditions in hand, the scope of the reaction was studied with the hope that amide derivatives such as **3** could be directly prepared. Additional esters, such as methyl and ethyl iodoacetates, readily reacted with the fused-ring aziridine to produce the desired oxazolidinone products **7b** and **7c** in excellent yields (Scheme 4; Table 2).



Scheme 4. General reaction of aziridine (**5**) with activated halides.

The reactions of the fused-ring aziridine and a series of amides were completely unsuccessful. Neither *N,N*-dimethyl iodoamide, *N*-methyl iodoamide or *N*-benzyl iodoamide provided any of the desired product. Interestingly, the reaction of *N,N*-dimethyl iodoamide (entry 4) did provide a moderate yield of 4-iodomethyl-5-trityloxymethyl-oxazolidin-2-one (**7d**), again, suggesting that ring opening of the aziridine by the iodide ion was a key step of the reaction. The α -iodo ketone, iodo-1-phenylethanone, provided product **7g** in 54% yield (entry 7). Iodoacetonitrile did not generate any addition product (entry 8). Activated halides, such as benzyl iodide (87%, entry 9), also provided the addition product.


With the success of the reactions of the fused-ring aziridines with the iodides, the reactions with select bromides were also examined. *Tert*-butylbromoacetate readily underwent reaction with aziridine **5** to provide the oxazolidinone **7j** in 74% yield, which was somewhat lower than the reaction with the corresponding iodide. Unlike the reactions with iodides, the addition of NaBr to the reaction did not improve the yield, and, instead, led to decomposition of the starting material. As with the iodoamides, the bromoamide (entry 12) did not provide any of the expected product. The reaction of benzyl bromide with aziridine **5** gave a lower yield of the oxazolidinone product than the corresponding iodide (entry 9 vs. entry 13). The use of α -tosyloxy-methyl acetate was also unsuccessful in providing the alkylated oxazolidinone product (entry 14).

Table 2. Reactions of aziridine (5) with activated halides


Entry	Compound #	X	R	Additive	Conditions	Yield (%)
1	7a	I	CH ₂ CO ₂ ^t Bu	NaI	Reflux	83
2	7b	I	CH ₂ CO ₂ Me	NaI	Reflux	90
3	7c	I	CH ₂ CO ₂ Et	NaI	Reflux	99
4	7d	I	CH ₂ CON(CH ₂) ₄	NaI	Reflux	0 ^a
5	7e	I	CH ₂ CONHMe	NaI	Reflux	0
6	7f	I	CH ₂ CONHBn	NaI	Reflux	0
7	7g	I	CH ₂ COPh	NaI	Reflux	54
8	7h	I	CH ₂ CN	NaI	Reflux	0
9	7i	I	CH ₂ Ph	NaI	Reflux	87
10	7j	Br	CH ₂ CO ₂ ^t Bu		Reflux	74
11	7j	Br	CH ₂ CO ₂ ^t Bu	NaBr	Reflux	0
12	7k	Br	CH ₂ CON(CH ₂) ₄		Reflux	0
13	7l	Br	CH ₂ Ph		Reflux	53
14	7m	OTs	CH ₂ CO ₂ Me		Reflux	0

^a 4-Iodomethyl-5-trityloxymethyl-oxazolidin-2-one was obtained in 74% yield.

Given the lack of success using α -halo amides in the iodide-mediated ring-opening/alkylation sequence, an alternate route to the desired amides (**4**) was designed. The reaction of an amine with a lactone such as **8** could provide a facile route to a variety of glycine substituted oxazolidinones (**4**). A silver-catalyzed cyclization of the iodomethyl group with the *t*-butyl ester might be expected to provide the bicyclic lactone (**8**).¹⁹ It was hoped that the *t*-butyl ester would react with the incipient cation formed by reaction of the iodide and silver salt. This would then release the *t*-butyl cation and provide **8**. Subsequent opening of **8** with an amine would provide the glycine substituted oxazolidinone **4** as shown in Scheme 5.


**Scheme 5.** Proposed route to glycine amide **4** from iodide **7a**.

Multiple attempts to generate the lactone **8** directly from **7a** were unsuccessful. Multiple silver salts, solvent, and temperatures were investigated without success. In order to carry out a formation of the lactone **8**, an alternate approach from the corresponding carboxylic acid was examined (Scheme 6).

**Scheme 6.** Conversion of iodide **7** to bicycle **8**.

Treatment of ester **7b** with LiOH in THF/H₂O at 0 °C provided acid **9** in excellent yield. With the carboxylic acid **9** in hand, the cyclization reaction promoted by different silver salts was studied.¹⁹ Silver trifluoroacetate²⁰ led only to the loss of the trityl group. Adding Na₂CO₃ to the silver trifluoroacetate to buffer the reaction did not lead to product either. Silver acetate provided lactone **8** in only 17% yield, again with significant loss of the trityl group. Addition of Na₂CO₃ did not help since none of the expected lactone was obtained under these conditions. Ultimately, silver oxide was found to be the best silver source, with a 78% yield of the product in CH₂Cl₂. Upon changing the solvent to CH₃CN, the yield was increased to 88%.¹⁰

With the key bicyclic lactone **8** in hand, the reactions of the lactone moiety with amines could be examined. Gratifyingly, it was found that the fused-ring lactone moiety **8** could readily react with primary amines to provide the desired products **4** in excellent yields (89%-100%) (Scheme 7; Table 3).




Scheme 7. Reaction of lactone **8** with a series of amines.

Simple primary amines such as methyl, isopropyl, isobutyl, allyl, and benzyl, and 4-methoxybenzylamine all provided amides **4a-4f** in excellent yield. Methoxyethyl amine, as well as hydroxyethyl amine, provided amides **4g** and **4h**, respectively. Glycine derivatives, such as glycine N-methyl amide and glycine methyl ester, both provided the corresponding amide derivatives **4i** and **4j** in excellent yields. The use of the secondary amine, dibutyl amine, provided none of the expected amide.

Table 3. Results of reactions of lactone **8** with amines

Entry	Product	R ¹ , R ²	Yield (%)
1	4a	R ¹ = CH ₃ , R ² = H	100
2	4b	R ¹ = iPr, R ² = H	100
3	4c	R ¹ = CH ₂ CH(CH ₃) ₂ , R ² = H	90
4	4d	R ¹ = allyl, R ² = H.	100
5	4e	R ¹ = Bn, R ² = H	93
6	4f	R ¹ = CH ₂ (4-OCH ₃ C ₆ H ₄) R ² = H	90
7	4g	R ¹ = CH ₂ CH ₂ OCH ₃ , R ² = H	100
8	4h	R ¹ = CH ₂ CH ₂ OH, R ² = H	89
9	4i	R ¹ = CH ₂ C(O)NHCH ₃ , R ² = H	90
10	4j	R ¹ = CH ₂ C(O)OCH ₃ , R ² = H	96
11	4k	R ¹ = R ² = nBu	0

The free alcohol resulting from the amine opening of the lactone was subsequently acylated to demonstrate a route to potential peptidomimetics. It was found that Steglich-esterification conditions worked quite well to provide a small series of ester derivatives from amide **4a** (Scheme 8). 2-Methyl propanoic acid and 4-Pentynoic acid provided the expected products **10a** and **10b** in yields of 81 and 85%, respectively. The amino acid Boc-glycine provided **10c** in 77% yield.

Scheme 8. Acylation of alcohol **4a**.

Conclusions

The synthesis of a novel class of oxazolidinone peptidomimetic has been described. This method uses a new reaction of fused-ring aziridines with activated halides to generate N-alkyl and N-acyl oxazolidinones from a fused-ring aziridine. This ring-opened product has been converted to a bicyclic lactone which readily reacts with primary amines to generate oxazolidinone glycinamides. Further studies on the synthesis of peptidomimetics based on these results will be reported in due course.

Experimental Section

General. ¹H NMR (300 MHz or 500 MHz) and ¹³C NMR spectra were measured on a Bruker Avance 300 MHz or 500 MHz NMR spectrometer with TMS used as the internal standard. High Resolution Mass Spectrometry (HRMS) measurements were performed on a Bruker 12 Tesla APEX –Qe FTICR-MS or Q Exactive Plus from Thermo Scientific. CH₂Cl₂ and THF were dried using a SOLVTEK solvent purification system. CH₃CN was distilled from CaH₂ and stored over molecular sieves. All amines were purified by distillation prior to use. Aziridine **5** was prepared as previously reported.¹⁰ All reactions were conducted under an atmosphere of argon. All other reagents were used as purchased. Chromatography refers to flash chromatography on silica gel according to the method of Still.²¹ The *R**/*S** notation is intended to indicate relative stereochemistry.²²

General Procedure A. Reaction of bicyclic lactone (8) with amines: The desired amine (200 mol%) was added to a solution of lactone compound **8** in CH₃CN (0.05M). The mixture was stirred at room temperature until the reaction was complete as determined by TLC. The solvent was removed and compound **4** was purified via column chromatography (CH₂Cl₂:MeOH; 15:1).

2-((4*R,5*S**)-4-Hydroxymethyl-2-oxo-5-trityloxymethyl-oxazolidin-3-yl)-*N*-methylacetamide (4a).** Compound **4a** (43 mg, 96%) was obtained as a white solid from **8** (42 mg, 0.1 mmol) and methylamine (6.2 mg methylamine in 12.4 mg of methanol, 0.2 mmol) following General Procedure A; mp 179-181 °C; ¹H NMR (CDCl₃, 500 MHz) δ 7.48-7.46 (m, 6H), 7.35-7.32 (m, 6H), 7.28-7.25 (m, 3H), 6.14 (br s, 1H), 4.83-4.81 (m, 1H), 4.59 (q, *J* 4.5 Hz, 1H), 4.20 (d, *J* 16.0 Hz, 1H), 3.72 (dd, *J* 3.0, 13.0 Hz, 1H), 3.60-3.57 (m, 2H), 3.46-3.43 (m, 2H), 3.19 (dd, *J* 4.0, 10.5 Hz, 1H), 2.81 (d, *J* 4.5, 3H). ¹³C NMR (CDCl₃, 125 MHz) δ 170.0, 158.6, 143.3, 128.5, 128.1, 127.4, 87.0, 75.3, 63.9, 61.9, 60.6, 46.3, 26.5. HRMS-ESI: *m/z* [M+Na]⁺ calcd for C₂₇H₂₈N₂O₅Na⁺: 483.1890; Found: 483.1891.

2-((4*R,5*S**)-4-Hydroxymethyl-2-oxo-5-trityloxymethyl-oxazolidin-3-yl)-*N*-isopropylacetamide (4b).** Compound **4b** (40 mg, yield 84%) was obtained as a white solid from **8** (42 mg, 0.1 mmol) and isopropyl amine (12 mg, 0.2

mmol) following General Procedure A; mp 128-130 °C; ^1H NMR (CDCl_3 , 500 MHz) δ 7.48-7.46 (m, 6H), 7.35-7.32 (m, 6H), 7.28-7.25 (m, 3H), 4.61 (q, J 4.5 Hz, 1H), 4.17 (d, J 17.0 Hz, 1H), 4.01 (sept, J 6.5 Hz, 1H), 3.81 (d, J 17.0 Hz, 1H), 3.73-3.67 (m, 2H), 3.42-3.36 (m, 2H), 3.22 (dd, J 4.5, 10.5 Hz, 1H), 1.14 (d, J 6.5 Hz, 3H), 1.13 (d, J 6.5 Hz, 3H). ^{13}C NMR (Acetone- d_6 , 125 MHz) δ 170.7, 159.5, 145.6, 130.4, 129.7, 128.9, 88.3, 76.7, 66.3, 62.9, 61.7, 47.4, 43.2, 23.5. HRMS-ESI: m/z $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{29}\text{H}_{32}\text{N}_2\text{O}_5\text{Na}^+$: 511.2203; Found: 511.2213.

2-((4R*,5S*)-4-Hydroxymethyl-2-oxo-5-trityloxymethyl-oxazolidin-3-yl)-N-isobutylacetamide (4c). Compound **4c** (300 mg, 90%) was obtained as white solid from compound **8** (290 mg, 0.7 mmol) and isobutyl amine (102 mg, 1.4 mmol) following General Procedure A; mp 128-131 °C; ^1H NMR (Acetone- d_6 , 500 MHz) δ 7.16 (br s, 1H), 7.48-7.46 (m, 6H), 7.38-7.33 (m, 6H), 7.29-7.26 (m, 3H), 5.16 (dd, J 4.0, 10.0 Hz, 1H), 4.61 (q, J 4.5 Hz, 1H), 4.22 (d, J 17.0 Hz, 1H), 3.88 (d, J 17.0 Hz, 1H), 3.74-3.70 (m, 2H), 3.42-3.64 (m, 2H), 3.23 (dd, J 4.5, 10.5 Hz, 1H), 3.10-3.04 (m, 2H), 1.83-1.73 (m, 1H), 0.90 (d, J 6.5 Hz, 6H). ^{13}C NMR (Acetone- d_6 , 125 MHz) δ 171.7, 159.5, 145.6, 130.4, 129.7, 128.9, 88.3, 76.7, 66.3, 62.9, 61.6, 48.4, 47.3, 21.3, 15.4. HRMS-ESI: m/z $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{30}\text{H}_{34}\text{N}_2\text{O}_5\text{Na}^+$: 525.2360; Found: 525.2355

N-Allyl-2-((4R*,5S*)-4-hydroxymethyl-2-oxo-5-trityloxymethyl-oxazolidin-3-yl)-N-acetamide (4d). Compound **4d** (46 mg, 98%) was obtained as a white solid from compound **8** (42 mg, 0.1 mmol) and allyl amine (11 mg, 0.2 mmol) following General Procedure A; mp 152-154 °C; ^1H NMR (CDCl_3 , 500 MHz) δ 7.40-7.39 (m, 6H), 7.30-7.26 (m, 6H), 7.23-7.20 (m, 3H), 6.89 (t, J 5.0 Hz, 1H), 5.80-5.72 (m, 1H), 5.17 (dd, J 1.0, 17.0 Hz, 1H), 5.11 (dd, J 1.0, 10.0 Hz, 1H), 4.63 (q, J 4.5 Hz, 1H), 4.30 (d, J 16.5 Hz, 1H), 3.89-3.83 (m, 1H), 3.80-3.75 (m, 1H), 3.70-3.69 (m, 1H), 3.57 (d, J 16.5 Hz, 1H), 3.53-3.52 (m, 1H), 3.44-3.41 (m, 1H), 3.40 (dd, J 4.5, 10.5 Hz, 1H), 3.18 (dd, J 4.0, 10.5 Hz, 1H). ^{13}C NMR (CDCl_3 , 125 MHz) δ 169.5, 158.6, 143.3, 133.1, 128.5, 128.1, 127.4, 117.0, 87.0, 75.2, 63.9, 62.0, 60.6, 46.4, 42.3. HRMS-ESI: m/z $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{29}\text{H}_{30}\text{N}_2\text{O}_5\text{Na}^+$: 509.2347; Found: 509.2052.

N-Benzyl-2-((4R*,5S*)-4-hydroxymethyl-2-oxo-5-trityloxymethyl-oxazolidin-3-yl)acetamide (4e). Compound **4e** (94 mg, 93%) was obtained as a clear oil from compound **8** (81 mg, 0.20 mmol) and benzyl amine (43 mg, 0.4 mmol) following General Procedure A; ^1H NMR (CDCl_3 , 300 MHz) δ 7.40-7.37 (m, 6H), 7.29-7.20 (m, 15H), 5.09-5.07 (m, 1H), 4.59 (q, J 4.8 Hz, 1H), 4.38 (dd, J 5.7, 14.7 Hz, 1H), 4.29-4.21 (m, 1H), 4.25 (d, J 17.1 Hz, 1H), 3.68-3.64 (m, 1H), 3.51 (d, J 16.5 Hz, 1H), 3.44-3.32 (m, 3H), 3.14 (dd, J 3.7, 10.4 Hz, 1H). ^{13}C NMR (CDCl_3 , 125 MHz) δ 169.5, 158.6, 143.3, 137.5, 128.7, 128.5, 128.1, 127.8, 127.6, 127.3, 86.9, 75.2, 63.9, 61.8, 60.4, 46.3, 43.7. HRMS-ESI: m/z $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{33}\text{H}_{32}\text{N}_2\text{O}_5\text{Na}^+$: 559.2203; Found: 559.2201

N-(4-Methoxybenzyl)-2-((4R*,5S*)-4-hydroxymethyl-2-oxo-5-trityloxymethyl-oxazolidin-3-yl)-acetamide (4f). Compound **4f** (50 mg, 90%) was obtained as a white solid from compound **8** (42 mg, 0.1 mmol) and 4-methoxybenzyl amine (27 mg, 0.2 mmol) following General Procedure A; mp 121-124 °C; ^1H NMR (CDCl_3 , 500 MHz) δ 7.40-7.38 (m, 6H), 7.30-7.26 (m, 6H), 7.23-7.21 (m, 3H), 7.16 (d, J 8.5 Hz, 2H), 6.83 (d, J 8.5 Hz, 2H), 6.73 (t, J 5.5 Hz, 1H), 4.92 (dd, J 4.5, 9.5 Hz, 1H), 4.60 (q, J 4.5 Hz, 1H), 4.37 (d, J 5.5, 14.5 Hz, 1H), 4.30-4.23 (m, 2H), 3.77 (s, 3H), 3.71-3.68 (m, 1H), 3.55-3.51 (m, 2H), 3.44-3.38 (m, 2H), 3.17 (dd, J 4.0, 10.0 Hz, 1H). ^{13}C NMR (CDCl_3 , 125 MHz) δ 69.3, 159.0, 158.5, 143.3, 129.5, 129.2, 128.5, 128.0, 127.3, 114.1, 86.9, 75.2, 63.9, 61.8, 60.4, 55.2, 46.3, 43.2. HRMS-ESI: m/z $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{35}\text{H}_{36}\text{N}_2\text{O}_5\text{Na}^+$: 587.2522; Found: 587.2520

2-((4R*,5S*)-4-hydroxymethyl-2-oxo-5-trityloxymethyl-oxazolidin-3-yl)-N-(2-methoxyethyl)acetamide (4g). Compound **4g** (43 mg, 87%) was obtained as a white solid from compound **8** (42 mg, 0.1 mmol) and methoxyethylamine (15 mg, 0.2 mmol) following General Procedure A; mp 141-145 °C; ^1H NMR (CDCl_3 , 500 MHz) δ 7.41-7.40 (m, 6H), 7.30-7.29 (m, 6H), 7.26-7.21 (m, 3H), 6.83 (br s, 1H), 4.93 (br s, 1H), 4.64 (q, J 4.5 Hz, 1H), 4.35 (d, J 17.0 Hz, 1H), 3.71-3.68 (m, 1H), 3.54-3.46 (m, 5H), 3.44-3.37 (m, 3H), 3.35 (s, 3H), 3.19 (dd, J 4.0, 10.0 Hz, 1H). ^{13}C NMR (CDCl_3 , 125 MHz) δ 169.5, 158.5, 143.3, 128.6, 128.0, 127.3, 86.9, 74.9, 70.7, 63.8, 62.0, 60.3, 58.8, 46.8, 58.8, 46.8, 39.5. HRMS-ESI: m/z $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{29}\text{H}_{32}\text{N}_2\text{O}_6\text{Na}^+$: 527.2153; Found: 527.2156.

N-(2-hydroxyethyl)-2-((4R*,5S*)-4-hydroxymethyl-2-oxo-5-trityloxymethyl-oxazolidin-3-yl)acetamide (4h). Compound **4h** (43 mg, 89%) was obtained as a white solid from compound **8** (42 mg, 0.1 mmol) and ethanolamine (12 mg, 0.2 mmol) following General Procedure A; mp 157-160 °C; ¹H NMR (CDCl₃, 500 MHz) δ 7.48-7.45 (m, 1H), 7.39-7.37 (m, 6H), 7.29-7.26 (m, 6H), 7.22-7.19 (m, 3H), 5.11 (br s, 1H), 4.61 (q, *J* 4.3 Hz, 1H), 4.28 (d, *J* 17.0 Hz, 1H), 4.92 (br s, 1H), 3.69-3.57 (m, 3H), 3.59 (d, *J* 17.0 Hz, 1H), 3.48-3.47 (m, 2H), 3.38-3.36 (m, 2H), 3.18-3.17 (m, 1H), 3.16 (dd, *J* 4.0, 10.5 Hz, 1H). ¹³C NMR (CDCl₃, 125 MHz) δ 170.0, 158.9, 143.3, 128.5, 128.0, 127.3, 86.9, 75.4, 63.9, 61.7, 61.0, 60.2, 46.4, 42.3. HRMS-ESI: *m/z* [M+Na]⁺ calcd for C₂₈H₃₀N₂O₆Na⁺: 513.1996; Found: 513.2005

2-((4R*,5S*)-4-hydroxymethyl-2-oxo-5-trityloxymethyl-oxazolidin-3-yl)-N-(2-(methylamino)-2-oxoethyl)acetamide (4i). Compound **4i** (86 mg, 90%) was obtained as a white solid from compound **8** (80 mg, 0.19 mmol) and N-methylglycinamide (33 mg, 0.38 mmol) following General Procedure A; mp 155-159 °C; ¹H NMR (CDCl₃, 500 MHz) δ 7.76 (t, *J* 5.1 Hz, 1H), 7.40-7.39 (m, 6H), 7.30-7.27 (m, 6H), 7.24-7.21 (m, 3H), 6.88 (d, *J* 4.1 Hz, 1H), 5.77 (s, 1H), 4.62 (q, *J* 4.2 Hz, 1H), 4.34 (d, *J* 17.0 Hz, 1H), 4.06 (dd, *J* 6.5, 16.5 Hz, 1H), 3.78-3.72 (m, 1H), 3.63 (d, *J* 17.0 Hz, 1H), 3.56-3.55 (m, 2H), 3.47-3.41 (m, 2H), 3.18 (dd, *J* 3.3, 10.3 Hz, 1H), 2.75 (d, *J* 4.3 Hz, 3H). HRMS-ESI: *m/z* [M+Na]⁺ calcd for C₂₉H₃₁N₃O₆Na⁺: 540.2105; Found: 540.2109.

Methyl 2-((4R*,5S*)-4-hydroxymethyl-2-oxo-5-trityloxymethyl-oxazolidin-3-yl)acetyl)glycinate (4j). 50 mg (96%) of compound **4j** was obtained as a white solid from compound **8** (42 mg, 0.1 mmol) and glycine methyl ester (18 mg, 0.2 mmol) following General Procedure A; mp 124-127 °C; ¹H NMR (CDCl₃, 500 MHz) δ 7.40-7.39 (m, 6H), 7.30-7.28 (m, 6H), 7.26-7.21 (m, 4H), 4.62 (q, *J* 4.5 Hz, 1H), 4.41 (d, *J* 17.0 Hz, 1H), 4.08 (dd, *J* 5.5, 18.0 Hz, 1H), 3.75-3.71 (m, 1H), 3.71 (s, 3H), 3.63 (d, *J* 17.0 Hz, 1H), 3.58-3.55 (m, 1H), 3.47-3.41 (m, 2H), 3.17 (dd, *J* 4.0, 10.0 Hz, 1H). ¹³C NMR (CDCl₃, 125 MHz) δ 170.7, 169.9, 158.7, 143.3, 128.6, 128.1, 127.4, 57.0, 75.1, 63.8, 61.9, 60.4, 52.6, 46.8, 41.1. HRMS-ESI: *m/z* [M+Na]⁺ calcd for C₂₉H₃₀N₂O₇Na⁺: 541.1945; Found: 541.1947.

General Procedure B. Addition reaction of aziridine (3) and alkyl iodides. Fused-ring aziridine **5**, NaI (200 mol%) and the requisite alkyl iodide (200 mol%) were dissolved in CH₃CN (0.03 M) and the mixture was stirred while under reflux until the reaction was complete as determined by TLC. The solvent was removed and the product was purified via column chromatography (Ethyl acetate:hexanes; 1:2).

tert-Butyl 2-((4S*,5S*)-4-iodomethyl-2-oxo-5-trityloxymethyl-oxazolidin-3-yl)acetate (7a). Following General Procedure B, compound **7a** (73 mg, 83%) was obtained from compound **5** (52 mg, 0.14 mol) and tert-butyl iodoacetate (68 mg, 0.28 mmol) as a white solid; mp 115-117 °C; ¹H NMR (CDCl₃, 500 MHz) δ = 7.46-7.44 (m, 6H), 7.33-7.30 (m, 6H), 7.26-7.23 (m, 3H), 4.25 (q, *J* 5.0 Hz, 1H), 4.13 (d, *J* 17.9 Hz, 1H), 4.11-4.10 (m, 1H), 3.82 (q, *J* 4.9 Hz, 1H), 3.70 (d, *J* 8.0 Hz, 1H), 3.45 (dd, *J* 5.0, 10.3 Hz, 1H), 3.37 (dd, *J* 4.8, 10.4 Hz, 1H), 3.23 (d, *J* 4.8 Hz, 2H), 1.44 (s, 9H). ¹³C NMR (CDCl₃, 75 MHz) δ = 167.2, 157.2, 143.3, 128.6, 128.0, 127.3, 87.2, 82.7, 78.7, 63.9, 57.6, 44.1, 28.1, 6.9. HRMS-ESI: *m/z* [M+Na]⁺ calcd for C₃₀H₃₂INO₅Na⁺: 636.1217; Found: 636.1210.

Methyl 2-((4S*,5S*)-4-iodomethyl-2-oxo-5-trityloxymethyl-oxazolidin-3-yl)acetate (7b). Following General Procedure B, compound **7b** (1.28 g, 90%) was obtained from compound **5** (0.93 g, 2.5 mol) and methyl iodoacetate (1.0 g, 5 mmol) as a white solid; mp 143-146 °C; ¹H NMR (CDCl₃, 300 MHz) δ = 7.46-7.43 (m, 6H), 7.34-7.25 (m, 9H), 4.29-4.23 (m, 2H), 3.87-3.81 (m, 2H), 3.70 (s, 3H), 3.48 (dd, *J* 5.0, 10.4 Hz, 1H), 3.34 (dd, *J* 4.5, 10.4 Hz, 1H), 3.23 (d, *J* 4.9 Hz, 1H). ¹³C NMR (CDCl₃, 75 MHz) δ = 168.7, 157.2, 143.3, 128.6, 128.1, 127.3, 87.2, 78.9, 63.7, 57.5, 52.5, 43.4, 6.8. HRMS-ESI: *m/z* [M+Na]⁺ calcd for C₂₇H₂₆NO₅Na⁺: 594.0748; Found: 594.0744.

Ethyl 2-((4S*,5S*)-4-iodomethyl-2-oxo-5-trityloxymethyl-oxazolidin-3-yl)acetate (7c). Following General Procedure B, compound **7c** (83 mg, 99%) was obtained from compound **5** (52 mg, 0.14 mol) and ethyl iodoacetate (60 mg, 0.28 mmol) as a white solid; mp 135-138 °C; ¹H NMR (CDCl₃, 300 MHz) δ = 7.46-7.43 (m,

6H), 7.34-7.24 (m, 9H), 4.28-4.25(m, 4H), 3.85-3.82 (m, 2H), 3.46 (dd, *J* 5.0, 10.4 Hz, 1H), 3.36 (dd, *J* 4.5, 10.4 Hz, 1H), 3.23 (d, *J* 4.8 Hz, 1H). ¹³C NMR (CDCl₃, 75 MHz) δ = 168.2, 157.2, 143.3, 128.6, 128.0, 127.3, 87.2, 78.8, 63.8, 61.7, 57.6, 43.5, 6.8. HRMS-ESI: *m/z* [M+Na]⁺ calcd for C₂₈H₂₈INO₅Na⁺: 608.0904; Found: 608.0899.

(4S*,5S*)-4-Iodomethyl-3-(2-oxo-2-phenylethyl)-5-trityloxymethyl-oxazolidin-2-one (7h). Following General Procedure B, compound **7h** (47 mg, 54%) was obtained from compound **5** (52 mg, 0.14 mmol) and α-iodoacetophenone (69 mg, 0.28 mmol) as a white solid; mp 107-109 °C; ¹H NMR (CDCl₃, 300 MHz) δ = 7.96-7.93 (m, 2H), 7.64-7.59 (m, 1H), 7.51-7.46 (m, 8H), 7.34-7.22 (m, 10H), 4.96 (d, *J* 18.2 Hz, 1H), 4.46 (d, *J* 18.2 Hz, 1H), 4.27 (q, *J* 5.0 Hz, 1H), 3.94-3.89 (m, 1H), 3.52 (dd, *J* 5.1, 10.4 Hz, 1H), 3.42 (dd, *J* 5.1, 10.4 Hz, 1H), 3.25 (dd, *J* 6.0, 11.2 Hz, 1H), 3.18(dd, *J* 3.2, 11.2 Hz, 1H). ¹³C NMR (CDCl₃, 75 MHz) δ = 193.2, 157.5, 143.4, 134.5, 134.1, 129.0, 128.7, 128.0, 127.3, 87.3, 79.0, 63.9, 57.6, 48.1, 7.3. HRMS-ESI: *m/z* [M+Na]⁺ calcd for C₃₂H₂₈INO₄Na⁺: 640.0955; Found: 640.0950.

(4S*,5S*)-3-Benzyl-4-iodomethyl-5-trityloxymethyl-oxazolidin-2-one (7j). Following General Procedure B, compound **7j** (57 mg, 87%) was obtained from compound **5** (52 mg, 0.14 mmol) and benzyl iodide (61 mg, 0.28 mmol) as a white solid; mp 112-115 °C; ¹H NMR (CDCl₃, 300 MHz) δ = 7.38-7.35 (m, 7H), 7.30-7.18 (m, 13H), 4.80 (d, *J* 15.4 Hz, 1H), 4.22 (q, *J* 4.2 Hz, 1H), 4.10 (d, *J* 15.2 Hz, 1H), 3.49 (dd, *J* 4.3, 10.6 Hz, 1H), 3.33-3.28 (m, 1H), 3.13-3.04 (m, 2H), 2.98 (dd, *J* 2.6, 11.0 Hz, 1H); 157.6, 143.0, 137.1, 128.9, 128.6, 128.1, 128.0, 127.3, 90.1, 78.2, 63.3, 58.0, 47.3, 22.0.; HRMS-ESI: *m/z* [M+Na]⁺ calcd for C₃₁H₂₈INO₃Na⁺: 612.1006; Found: 612.1010.

General Procedure C for the addition reaction of aziridine 5 and alkyl bromides. The desired bromide (200 mol%) was added to a solution of Compound **5** in CH₃CN (0.03 M) and the reaction was stirred under reflux until the reaction was complete as determined by TLC. The solvent was removed and the product was purified via column chromatography (Ethyl acetate:hexanes; 1 :2).

tert-Butyl 2-((4S*,5S*)-4-bromomethyl-2-oxo-5-trityloxymethyl-oxazolidin-3-yl)acetate (7l). Following General Procedure C, compound **7l** (52 mg, 74%) was obtained from compound **5** (52 mg, 0.14 mmol) and tert-butyl bromoacetate (54.6 mg, 0.28 mmol) as a white solid after column chromatography; mp 119-123 °C; ¹H NMR (CDCl₃, 300 MHz) δ = 7.46-7.43 (m, 6H), 7.34-7.22 (m, 9H), 4.36 (q, 1H, *J* 5.0 Hz), 4.16-4.06 (m, 2H), 3.78 (d, *J* 18.0 Hz, 1H), 3.44-3.43 (m, 4H). ¹³C NMR (CDCl₃, 75 MHz) δ = 167.3, 157.2, 143.3, 128.6, 128.0, 127.3, 87.2, 82.7, 76.6, 63.9, 58.1, 44.4, 32.1, 28.1. HRMS-ESI: *m/z* [M+Na]⁺ calcd for C₃₀H₃₂BrNO₅Na⁺: 588.1356; Found: 588.1352.

(4S*,5S*)-3-Benzyl-4-bromomethyl-5-trityloxymethyl-oxazolidin-2-one (7n). Following General Procedure C, compound **7n** (40 mg, 53%) was obtained from compound **5** (52 mg, 0.14 mmol) and benzylbromide (47.9 mg, 0.28 mmol) as a white solid after column chromatography; mp 99-102 °C; ¹H NMR (CDCl₃, 300 MHz) δ = 7.37-7.36 (m, 6H), 7.29-7.20 (m, 14H), 4.80 (d, *J* 15.4 Hz, 1H), 4.38 (q, *J* 3.9 Hz, 1H), 4.15 (d, *J* 15.4 Hz, 1H), 3.61-3.60 (m, 1H), 3.48 (dd, *J* 4.4, 10.5 Hz, 1H), 3.28 (dd, *J* 6.0, 11.2 Hz, 1H), 3.16-3.14 (m, 1H), 3.11 (dd, *J* 3.3, 10.5 Hz, 1H). ¹³C NMR (CDCl₃, 75 MHz) 157.5, 143.2, 135.1, 128.9, 128.6, 128.1, 128.0, 127.3, 87.2, 76.5, 63.3, 56.3, 46.3, 32.3. HRMS-ESI: *m/z* [M+Na]⁺ calcd for C₃₁H₂₈BrNO₃Na⁺: 564.1145; Found: 564.1149.

(1S*,8aR*)-1-(Trityloxymethyl)dihydro-1H,3H-oxazolo[4,3-c][1,4]oxazine-3,6(5H)-dione (8). Compound **9** (2.40 g, 4.3 mmol) was dissolved in 100 mL of CH₃CN and Ag₂O (1.60 g, 6.9 mmol) was added. The mixture was stirred at RT for 2 hours and the solvent was removed. After column chromatography (Petroleum ether : Ethyl acetate, 2:1) compound **8** (1.62 g, 88%) was obtained as a white solid; mp 136-139 °C; ¹H NMR (CDCl₃, 300 MHz) δ = 4.56 (d, 1H, *J* 19.2 Hz), 4.41 (dd, 1H, *J* 3.9, 11.0 Hz), 4.29 (t, 1H, *J* 10.9 Hz), 4.17-4.08 (m, 1H), 4.07 (d, 1H, *J* 19.2 Hz), 3.94-3.88 (m, 1H), 3.47 (dd, 1H, *J* 5.6, 10.4 Hz), 3.39 (dd, 1H, *J* 4.3, 10.4 Hz). ¹³C NMR (CDCl₃, 75

MHz) δ = 163.6, 155.8, 143.1, 128.4, 128.2, 127.5, 87.4, 74.5, 70.3, 63.3, 51.2, 43.5. HRMS-ESI: m/z $[M+Na]^+$ calcd for $C_{26}H_{23}NO_5Na^+$: 452.1468; Found: 452.1470.

2-((4S*,5S*)-4-Iodomethyl-2-oxo-5-trityloxymethyl-oxazolidin-3-yl)acetic acid (9). Compound **7b** (448 mg, 0.78 mmol) was dissolved in 25 mL of THF and the solution was cooled to 0 °C. LiOH (37 mg, 1.56 mmol) was dissolved in 5 mL of water and the aqueous solution was added to the solution of ester **7b**. The reaction mixture was stirred at 0 °C for 2 hours and the reaction was concentrated. The remaining aqueous solution was acidified by HCl (0.1 M) to pH 2, and the product was extracted with EtOAc (3 x 15 mL). The organic layer was dried over $MgSO_4$, filtered, concentrated and purified by column chromatography (Ethyl acetate:Petroleum ether, 1 :1). Compound **9** (370 mg, 85%) was obtained as white oil; 1H NMR ($CDCl_3$, 300 MHz) δ = 7.41-7.31 (m, 6H), 7.29-7.19 (m, 9H), 4.27-4.19 (m, 2H), 3.86-3.74 (m, 2H), 4.46 (dd, 1H, J 4.7, 10.5 Hz), 4.33 (dd, 1H, J 4.4, 10.5 Hz), 3.15 (d, 1H, J 4.7 Hz). ^{13}C NMR ($CDCl_3$, 75 MHz) δ = 172.2, 157.7, 143.3, 128.6, 128.1, 127.4, 87.2, 79.2, 63.7, 57.6, 43.3, 6.7. HRMS-ESI: m/z $[M+Na]^+$ calcd for $C_{26}H_{24}INO_5Na^+$: 580.059137; Found: 580.059185.

General procedure E. Reaction of compound 4a with carboxylic acid using *N,N'*-Dicyclohexylcarbodiimide (DCC). The requisite acid was dissolved in CH_2Cl_2 (0.03 M) then DCC (110 mol%), DMAP (10 mol%), and alcohol **4a** (110 mol%) was then added. The reaction mixture was stirred for 12 hours at rt and the precipitate was filtered off. The reaction was concentrated and purified via column chromatography ($CHCl_3$:iPrOH, 50:1).

(3-(2-Methylamino-2-oxoethyl)-2-oxo-5-trityloxymethyl-oxazolidin-4-yl)methyl isobutyrate (10a). Following General Procedure E, compound **10a** (61 mg, 81%) was obtained from compound **4a** (70 mg, 0.15 mmol) and isobutyric acid (15 mg, 0.17 mmol) as a white solid; mp 138-140 °C; 1H NMR ($CDCl_3$, 500 MHz) δ = 7.41-7.40 (m, 6H), 7.34-7.32 (m, 6H), 7.27-7.24 (m, 3H), 6.28 (br s, 1H), 4.36 (q, J 3.8 Hz, 1H), 4.27 (dd, J 3.5, 12.5 Hz, 1H), 4.10 (d, J 17.0 Hz, 1H), 4.04 (dd, J 3.5, 12.0 Hz, 1H), 3.86-3.83 (m, 1H), 3.83 (d, J 17.0 Hz, 1H), 3.62 (dd, J 4.0, 10.5 Hz, 1H), 3.14 (dd, J 3.0, 11.0 Hz, 1H), 2.53 (sept, J 7.0, 1H), 2.45 (d, J 5.0, 3H), 1.12 (d, J 7.0, 6H). ^{13}C NMR (Acetone, 500 MHz) δ = 176.4, 168.1, 158.0, 143.0, 128.6, 128.2, 127.5, 87.5, 75.3, 64.1, 61.6, 57.5, 46.3, 33.8, 25.9, 18.9, 18.9. HRMS-ESI: m/z $[M+Na]^+$ calcd for $C_{26}H_{23}NO_5Na^+$: 553.2309; Found: 553.2312.

(3-(2-Benzylamino-2-oxoethyl)-2-oxo-5-trityloxymethyl-oxazolidin-4-yl)methyl benzoate (10b). Following General Procedure E, compound **10b** (53 mg, 85%) was obtained from compound **4a** (52 mg, 0.10 mmol) and 4-pentynoic acid (11 mg, 0.11 mmol) as a white solid; mp 97-101 °C; 1H NMR ($CDCl_3$, 500 MHz) δ = 7.43-7.41(m, 6H), 7.34-7.31 (m, 6H), 7.28-7.25 (m, 3H), 6.25 (q, J 4.4, 1H), 4.37 (q, J 3.9, 1H), 4.10-4.04 (m, 2H), 3.87-3.84 (m, 2H), 3.60 (dd, J 3.9, 10.7 Hz, 1H), 3.16 (dd, J 3.2, 10.7 Hz, 1H), 2.55-2.45 (m, 7H), 1.96 (t, J 2.5 Hz, 1H). ^{13}C NMR ($CDCl_3$, 125 MHz) δ = 171.1, 168.1, 158.0, 143.0, 128.6, 128.2, 127.5, 87.5, 82.0, 75.2, 69.5, 64.0, 62.2, 57.5, 46.6, 33.1, 25.9, 14.3; HRMS-ESI: m/z $[M+Na]^+$ calcd for $C_{32}H_{32}N_2O_6Na^+$:563.2153; Found: 563.2154.

(3-(2-(Methylamino)-2-oxoethyl)-2-oxo-5-trityloxymethyl-oxazolidin-4-yl)methyl *N*-(*tert*-butoxycarbonyl)glycinate (10c). Following General Procedure E, compound **10c** (120 mg, 77%) was obtained from compound **4a** (110 mg, 0.20 mmol) and Boc-glycine (35 mg, 0.22 mmol) as a white solid; mp 198-202 °C; 1H NMR ($CDCl_3$, 500 MHz) δ = 7.41-7.40 (m, 6H), 7.33-7.30 (m, 6H), 7.27-7.26 (m, 3H), 6.42 (s, 1H), 5.28 (s, 1H), 4.29-4.25 (m, 2H), 4.10 (dd, J 5.3, 12.0 Hz, 1H), 3.99-3.79 (m, 5H), 3.56 (d, J 10.5 Hz, 1H), 3.18 (d, J 10.5 Hz, 1H), 2.55 (d, J 4.5 Hz, 3H), 1.44 (s, 9H). ^{13}C NMR ($CDCl_3$, 125 MHz) δ = 169.9, 168.3, 158.0, 156.0, 143.0, 128.6, 128.2, 127.5, 57.5, 87.5, 80.2, 74.9, 63.9, 63.6, 57.5, 47.0, 42.4, 28.3, 26.0; HRMS-ESI: m/z $[M+Na]^+$ calcd for $C_{34}H_{39}N_3O_8Na^+$: 640.2629; Found: 640.2627.

References

- 1 Perez, J. J. *Curr. Top. Med. Chem.* **2018**, *18*, 566-590.
<https://doi.org/10.2174/1568026618666180522075258>
- 2 Avan, I.; Hall, C. D.; Katritzky, A. R. *Chem. Soc. Rev.* **2014**, *43*, 3575-3594.
<https://doi.org/10.1039/c3cs60384a>
- 3 Trabocchi, A.; Guarna, A. *Peptidomimetics in Organic and Medicinal Chemistry*; Wiley, 2014.
<https://doi.org/10.1002/9781118683033>
- 4 Crowley, B. M.; Stump, C. A.; Nguyen, D. N.; Potteiger, C. M.; McWherter, M. A.; Paone, D. V.; Quigley, A. G.; Bruno, J. G.; Cui, D.; Culberson, J. C.; Danziger, A.; Fandozzi, C.; Gauvreau, D.; Kemmerer, A. L.; Menzel, K.; Moore, E. L.; Mosser, S. D.; Reddy, V.; White, R. B.; Salvatore, C. A.; Kane, S. A.; Bell, I. M.; Selnick, H. G.; Fraley, M. E.; Burgey, C. S. *Bioorg. Med. Chem. Lett.* **2015**, *25*, 4777-4781.
<https://doi.org/10.1016/j.bmcl.2015.07.021>
- 5 De Marco, R.; Greco, A.; Rupiani, S.; Tolomelli, A.; Tomasini, C.; Pieraccini, S.; Gentilucci, L. *Org. Biomol. Chem.* **2013**, *11*, 4316-4326.
<https://doi.org/10.1039/c3ob40357b>
- 6 Gentilucci, L.; Tolomelli, A.; De Marco, R.; Tomasini, C.; Feddersen, S. *Eur. J. Org. Chem.* **2011**, *25*, 4925-4930.
- 7 Ohta, Y.; Itoh, S.; Shigenaga, A.; Shintaku, S.; Fujii, N.; Otaka, A. *Org. Lett.* **2006**, *8*, 467-470.
<https://doi.org/10.1021/ol052755m>
- 8 Tomasini, C.; Luppi, G.; Monari, M. *J. Am. Chem. Soc.* **2006**, *128*, 2410-2420.
<https://doi.org/10.1021/ja056762h>
- 9 Elashal, H. E.; Raj, M. *Chem. Commun.* **2016**, *52*, 6304-6307.
<https://doi.org/10.1039/C6CC01509C>
- 10 Orac, C. M.; Zhou, S.; Means, J. A.; Boehm, D.; Bergmeier, S. C.; Hines, J. V. *J. Med. Chem.* **2011**, *54*, 6786-6795.
<https://doi.org/10.1021/jm2006904>
- 11 Bergmeier, S. C.; Stanchina, D. M. *J. Org. Chem.* **1999**, *64*, 2852-2859.
<https://doi.org/10.1021/jo9823893>
- 12 Anupam, R.; Nayek, A.; Green, N. J.; Grundy, F. J.; Henkin, T. M.; Means, J. A.; Bergmeier, S. C.; Hines, J. V. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 3541-3544.
<https://doi.org/10.1016/j.bmcl.2008.05.015>
- 13 Means, J.; Katz, S. J.; Anupam, R.; Nayek, A.; Hines, J. V.; Bergmeier, S. C. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 3600-3604.
<https://doi.org/10.1016/j.bmcl.2006.03.068>
- 14 Maciagiewicz, I.; Zhou, S.; Bergmeier, S. C.; Hines, J. V. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 4524-4527.
<https://doi.org/10.1016/j.bmcl.2011.05.130>
- 15 Hancock, M. T.; Pinhas, A. R. *Tet. Lett.* **2003**, *44*, 5457-5460.
[https://doi.org/10.1016/S0040-4039\(03\)01325-X](https://doi.org/10.1016/S0040-4039(03)01325-X)
- 16 Nonn, M.; Remete, A. M.; Fulop, F.; Kiss, L. *Tetrahedron* **2017**, *73*, 5461-5483.
<https://doi.org/10.1016/j.tet.2017.07.062>
- 17 Stankovic, S.; D'Hooghe, M.; Catak, S.; Eum, H.; Waroquier, M.; Van Speybroeck, V.; De Kimpe, N.; Ha, H.-J. *Chem. Soc. Rev.* **2012**, *41*, 643-665.
- 18 Lu, P. *Tetrahedron* **2010**, *66*, 2549-2560.

<https://doi.org/10.1016/j.tet.2010.01.077>

- 19 Caille, J. C.; Farnier, M.; Guillard, R.; Aubry, A.; Lecomte, C. *Can. J. Chem.* **1986**, *64*, 831-836.
<https://doi.org/10.1139/v86-136>
- 20 Jefford, C. W.; Sledeski, A. W.; Lelandais, P.; Boukouvalas, J. *Tet. Lett.* **1992**, *33*, 1855-1858.
[https://doi.org/10.1016/S0040-4039\(00\)74160-8](https://doi.org/10.1016/S0040-4039(00)74160-8)
- 21 Still, W. C.; Kahn, M.; Mitra, A. *J. Org. Chem.* **1978**, *43*, 2923-2925.
<https://doi.org/10.1021/jo00408a041>
- 22 Eliel, E. L.; Wilen, S. H. *Stereochemistry of Organic Compounds*; Wiley-Interscience, 1994.